Foxy-5 as Neo-Adjuvant Therapy in Subjects With Wnt-5a Low Colon Cancer
Status:
Recruiting
Trial end date:
2022-03-14
Target enrollment:
Participant gender:
Summary
Phase II study investigating the safety, tolerability and effect on disease reccurence of
Foxy-5 as neo-adjuvant therapy in resected colon cancer patients treated with FOLFOX
chemotherapy regimen. It is a two-arm study and patients will be randomised to receive either
standard therapy (surgery + FOLFOX 6 months regimen) or standard therapy + neo-adjuvant
administration of Foxy-5 prior to- and following surgery (maximum of 39 administrations)
until initiation of FOLFOX therapy.
Phase:
Phase 2
Details
Lead Sponsor:
WntResearch AB
Collaborators:
BioVica AB Catalan Institute of Oncology SAGA diagnostics AB SMS-Oncology BV Unilabs A/S